Supernus Pharmaceuticals SUPN Inventory write-downs
Inventory write-downs at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InventoryWriteDown.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's inventory write-downs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's inventory write-downs?
- Supernus Pharmaceuticals (SUPN) reported inventory write-downs of $1.82M in Q1 2026.
- How has Supernus Pharmaceuticals's inventory write-downs changed year-over-year?
- Supernus Pharmaceuticals's inventory write-downs increased by 231.8% year-over-year, from $547K to $1.82M.
- What is the long-term trend for Supernus Pharmaceuticals's inventory write-downs?
- Over 2 years (2022 to 2024), Supernus Pharmaceuticals's inventory write-downs has grown at a -7.7% compound annual growth rate (CAGR), from $10.44M to $8.91M.
- What does inventory write-downs mean?
- This represents the expense recognized when the carrying value of inventory is reduced due to obsolescence, damage, or a decline in market value below cost. It serves as a key indicator of supply chain health and product demand forecasting accuracy. High or frequent write-downs may signal challenges in inventory management or product lifecycle transitions.